• The pharmacological efficiency rate of the basic therapy the juvenile rheumatoid arthritis
en To content

The pharmacological efficiency rate of the basic therapy the juvenile rheumatoid arthritis


The pharmacological efficiency rate of the basic therapy the juvenile rheumatoid arthritis



National Medical University named afterM.I Pirogov, Vinnitsya, Ukraine


Purpose: the dynamic estimation the of the individual indicators of inflammatory response and the nuclear factor-kB content in response to basic therapy of the juvenile rheumatoid arthritis.

Patients and methods: There were 68 children with JRA under the observation. The first group of 32 children who got a methotrexate as a disease-modifying anti-rheumatic drugs. The second one of 25 patients who got a sulfasalazine as a basis therapy. The third group consist of 11 patients got a leflunomide as a DMAR. All the groups were presented according to the age, gender and disease duration.

Results: JRA duration among children is characterized with the significant increasing of the inflammatory response. The activity inhibition of the inflammatory process was observed among all groups of children. The answer was observed during the methotrexate treatment that got the decreasing indicators ИЛ-1β (на 63,7±3,7%), NF-kB (на 30,3±1,12%) in comparison with the treatment before and exceeded among the second and the third groups of children.

Conclusion: researching result identified the highest methotrexate therapeutic efficacy as JRA therapy basis drug according to clinical and laboratory indicators.



1. Алексеева Е. И. Алгоритм диагностики и лечения ювенильного артрита / Е. И. Алексеева, Т. М. Бзарова // Вопр. совр. педиатрии. — 2010. — № 6. — С. 78—104.

2. Бережний В. В. Клінічна ревматологія дитячого віку / В. В. Бережний, Т. В. Марушко, Ю. В. Марушко. — Черкаси : Видавець Чабаненко Ю., 2009. — 192 с.

3. Клинико-рентгенологическая динамика у пациента с системной формой ювенильного ревматоидного артрита на терапии этанерцептом / Е. С. Жолобова, С. Н. Чебышева, Н. А. Геппе [и др.] // Лечащий врач. — 2011. — № 4. — С. 83—85.

4. Цитокины при аутоиммунных и аллергических заболеваниях у детей / А. Б. Бакиров, А. У. Шагалина, Л. А. Фукалова, Л. М. Мясагутова // Цитокины и воспаление. — 2009. — № 7. — С. 92—94.

5. Castro-Rueda Heman. Biologic Therapy for Early Rheumatoid Arthritis: The Latest Evidence / Hernan Castro-Rueda, Arthur Kavanaugh // Current opinion in rheumatology. — 2008. — Vol. 3. — P. 314—319.

6. Dosa Laszlo. IL-6 Receptor Antibody Shows Promise for Juvenile Rheumatoid Arthritis / Laszlo Dosa // ACR 67th Annual Scientific Meeting. — 2009. — Abstract 1070.

7. German evidence and consensus based guidelines 2010 for the treatment of juvenile idiopathic arthritis (JIA) / G. Dueckers, N. Guellac, M. Arbogast [et al.] // Pediatrics Rheumatology. — 2011. — Vol. 9. — P. 181.

8. Miric M. Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis / M. Mircic, A. Kavanaugh // Expert Cell Research. — 2011. — Vol. 9. — P. 1286—1292.

9. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients / Spirchez M., Samasca G., Iancu M. [et al.] // Clinical Laboratory. — 2012. — Vol. 58. — P. 253—260.

10. Sandborg C. Pediatric rheumatic disease: Standards of care for JIA — the basic foundation for quality / C. Sandborg // National Review Rheumatology. — 2010. — Vol. 7. — P. 389—390.

11. Systematic review of disease_modifying antirheumatic drugs for juvenile idiopathic arthritis / Alex R Kemper, Heather A Van Mater, Remy R Coeytaux [et al.] // BMC Pediatrics. — 2012. — Vol. 29. — P. 1471—1479.